Published in Cancer Weekly, September 7th, 1998
The trial marks the first time this type of therapeutic vaccine has been used to study its effect on Prostate Specific Antigen (PSA) levels.
A total of 24 prostate cancer patients are evaluated in the Phase II trial, which monitors quality of life benefits, tumor suppression and PSA levels in treated patients. PRA conducts the multi-center study in the United States to conform with both U.S. and European regulatory approval...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.